Hoe verhoudt R9Q's PS Ratio zich tot zijn concurrenten?

R9Q is duur op basis van de Price-To-Sales -ratio ( 21.7 x) vergeleken met het gemiddelde van de peer ( 11.5 x).

Hoe verhoudt R9Q's PS Ratio zich tot andere bedrijven in de European Pharmaceuticals industrie?

R9Q is duur op basis van de Price-To-Sales -ratio ( 21.7 x) vergeleken met het German Pharmaceuticals -industriegemiddelde ( 2 x).

Wat is R9Q's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

R9Q is duur op basis van de Price-To-Sales Ratio ( 21.7 x) vergeleken met de geschatte Fair Price-To-Sales Ratio ( 0.5 x).

Wat is de reële prijs van R9Q als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van R9Q te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Recce Pharmaceuticals (DB:R9Q) - Aandelenkoers, Nieuws & Analyse

R9Q Overzicht aandelen

Recce Pharmaceuticals Ltd ontdekt, ontwikkelt en verkoopt synthetische anti-infectiva in Australië, het Verenigd Koninkrijk en de Verenigde Staten. Meer informatie

R9Q fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Risicoanalyse

Negatief eigen vermogen

De winst zal naar verwachting de komende drie jaar met gemiddeld 53.4% per jaar dalen.

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 3 meer risico's

Recce Pharmaceuticals Ltd Concurrenten

Redx Pharma

DB:0RX

€65.0m

MPH Health Care

DB:93M1

€103.6m

Pierrel

DB:2FJ0

€92.8m

Cantourage Group

XTRA:HIGH

€54.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Recce Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.26
52 Week Hoogtepunt	AU$0.38
52 Week Laag	AU$0.23
Bèta	1.13
11 maand verandering	-14.38%
3 maanden verandering	-0.76%
1 Jaar Verandering	-7.75%
33 jaar verandering	-50.57%
5 jaar verandering	n/a
Verandering sinds IPO	-19.11%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	R9Q	DE Pharmaceuticals	DE Markt
7D	-5.1%	-5.0%	-1.3%
1Y	-7.7%	-22.0%	7.4%

Rendement versus industrie: R9Q overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -22 % opleverde.

Rendement versus markt: R9Q presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.4 % opleverde.

Prijsvolatiliteit

Is R9Q's price volatile compared to industry and market?
R9Q volatility
R9Q Average Weekly Movement	11.2%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van R9Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van R9Q is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	n/a	James Graham	www.recce.com.au

Recce Pharmaceuticals Ltd ontdekt, ontwikkelt en commercialiseert synthetische anti-infectiva in Australië, het Verenigd Koninkrijk en de Verenigde Staten. De belangrijkste kandidaat is RECCE 327 (R327) voor de behandeling van bloedinfecties en sepsis veroorzaakt door E. coli en S. aureus bacteriën, inclusief hun superbug vormen. Het bedrijf ontwikkelt ook RECCE 529, een synthetisch anti-infectivum voor virale infecties; en RECCE 435, een synthetisch polymeerantibioticum voor oraal gebruik.

Recce Pharmaceuticals Ltd Samenvatting

Hoe verhouden de winst en inkomsten van Recce Pharmaceuticals zich tot de beurswaarde?
R9Q fundamentele statistieken
Marktkapitalisatie	€67.72m
Inkomsten(TTM)	-€10.98m
Inkomsten(TTM)	€3.12m

21.7x

P/S-verhouding

-6.2x

Koers/Winstverhouding

Is R9Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
R9Q resultatenrekening (TTM)
Inkomsten	AU$5.03m
Kosten van inkomsten	AU$7.22m
Brutowinst	-AU$2.19m
Overige uitgaven	AU$15.47m
Inkomsten	-AU$17.66m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.076
Brutomarge	-43.52%
Nettowinstmarge	-351.24%
Schuld/Eigen Vermogen Verhouding	-101.7%

Hoe presteerde R9Q op de lange termijn?

Bekijk historische prestaties en vergelijking

R9Q Overzicht aandelen

Risicoanalyse

Recce Pharmaceuticals Ltd Concurrenten

DB:0RX

€65.0m

DB:93M1

€103.6m

DB:2FJ0

€92.8m

XTRA:HIGH

€54.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recent updates

Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

New major risk - Share price stability

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

New minor risk - Financial data availability

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

New major risk - Share price stability

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

CEO, MD & Executive Director recently bought €190k worth of stock

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study

Less than half of directors are independent

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg

Less than half of directors are independent

Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong

Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327